Olaparib vs Talazoparib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: PARP · full HR+/HER2- Metastatic Breast Cancer pipeline

Olaparib

Marketed by AstraZeneca and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT02000622 · Phase 3 · completed

The trial randomly assigned 302 participants to olaparib or active chemotherapy, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, independently reviewed progression-free survival, was met: median PFS was 7.0 versus 4.2 months, with a hazard ratio of 0.58 (95% CI 0.43–0.80; p=0.0009).

Next expected readout: January 2027 · NCT04683679 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) (met)

Result source: NCT02000622

Talazoparib

Marketed by Pfizer and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT01945775 · Phase 3 · completed

Participants were randomized 2:1 to talazoparib or physician’s-choice chemotherapy, with 287 and 144 participants respectively, but treatment assignment was not blinded. The primary radiologic progression-free survival endpoint was met, with a statistically significant benefit for talazoparib; the open-label design and nonsignificant overall-survival result support a moderate evidence grade.

Next expected readout: January 2027 · NCT04039230 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) (met)

Result source: NCT01945775

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlaparibTalazoparib
PFS, median7 vs 4.2vs Chemotherapy300 mg bd · n 205NCT02000622
3 other results
8.6 vs 5.6vs Physician's Choice Treatmentn 287NCT01945775
8 other results
OS, median19.3 vs 19.6vs Chemotherapy300 mg bd · n 205NCT02000622
4 other results
  • 19.3 vs 17.1 300 mg bd · n 205 · Phase 3 · secondary NCT02000622
  • 19.3 vs 17.1 300 mg bd · n 205 · Phase 3 · secondary NCT02000622
  • 24.9 n 252 · Phase 3 · secondary NCT03286842
  • 8.9 n 11 · Phase 2 · secondary NCT03205761
19.3 vs 19.5vs Physician's Choice Treatmentn 287NCT01945775
ORR49.6%bn 252NCT0328684262.6% vs 27.2%vs Physician's Choice Treatmentn 219NCT01945775
Clinical benefit rate—Trial running · NCT02810743—Not reported

PFS, median

Olaparib
7 vs 4.2vs Chemotherapy300 mg bd · n 205NCT02000622
3 other results
Talazoparib
8.6 vs 5.6vs Physician's Choice Treatmentn 287NCT01945775
8 other results

OS, median

Olaparib
19.3 vs 19.6vs Chemotherapy300 mg bd · n 205NCT02000622
4 other results
  • 19.3 vs 17.1 300 mg bd · n 205 · Phase 3 · secondary NCT02000622
  • 19.3 vs 17.1 300 mg bd · n 205 · Phase 3 · secondary NCT02000622
  • 24.9 n 252 · Phase 3 · secondary NCT03286842
  • 8.9 n 11 · Phase 2 · secondary NCT03205761
Talazoparib
19.3 vs 19.5vs Physician's Choice Treatmentn 287NCT01945775

ORR

Olaparib
49.6%bn 252NCT03286842
Talazoparib
62.6% vs 27.2%vs Physician's Choice Treatmentn 219NCT01945775

Clinical benefit rate

Olaparib
—Trial running · NCT02810743
Talazoparib
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Olaparib: 7 of 7 rows · Talazoparib: 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlaparib
Rows use multiple source trials
Talazoparib
Rows use multiple source trials
Duration of Response
time to event · months
No placebo or comparator arm
8 monthsa,b,c,d
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1 other source trial
18.4 months
NCT03205761 · Phase 2 · registry result, not featured evidence
7.43 months*e,a,b,c,d
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 32.2 weeks as posted
show 3 more doses
6.21 months*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 26.9 weeks as posted
NA months
NCT01286987 · Phase 1 · registry result, not featured evidence
3.14 months*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 13.6 weeks as posted
ORR
event count · % of participants
No placebo or comparator arm
9.1% (n=11) @ 8wk*f,b,c,d
NCT03205761 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
40% (n=20)*e,f,b,c,d
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 8 participants as posted
show 6 more doses
0% (n=14)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
38.7% (n=31)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 12 participants as posted
15.4% (n=13)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=1)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=2)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
8.7% (n=23)*
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted
PFS
time to event · months
No placebo or comparator arm
8.18 monthsa,b,c,d
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1 other source trial
1.8 months @ 8wk
NCT03205761 · Phase 2 · registry result, not featured evidence
3.4 months1.0 mge,a,b,c,d
NCT03343054 · Phase 1 · registry result, not featured evidence
show 1 more dose
3 months0.75 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
Dropout rate
82.4%300 mg bdg
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 6 more results
—Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
52.6%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
36.2%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT03205761 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneh
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
0%Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
0%Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
5%Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
0%Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
—1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone0.75 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
—Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
83.3%1000 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%1100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
83.3%900 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%600 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%400 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%200 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%50 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%25 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Breast Cancer
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Ewing Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Ovarian/ Peri
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Pancreatic Ca
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Prostate Canc
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (SCLC Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—300 mg bdg
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 6 more results
—Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
0%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
3.1%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
—
NCT03205761 · Phase 2 · registry result, not featured evidence
—h
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
—Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
—Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
—Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
—Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
—1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
—1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
—Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
—1000 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—1100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—900 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—600 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—400 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—200 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—50 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—25 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Breast Cancer
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Ewing Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Ovarian/ Peri
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Pancreatic Ca
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (Prostate Canc
NCT01286987 · Phase 1 · registry result, not featured evidence
—Part 2: Talazoparib (SCLC Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
Serious AEs
18%300 mg bdg
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 6 more results
12.7%Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
33.3%Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
100%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
18.4%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
14.9%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
36.4%
NCT03205761 · Phase 2 · registry result, not featured evidence
36%h
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
0%Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
15%Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
5%Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
0%Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
0%1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
5.3%1.0 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
33.3%0.75 mg
NCT03343054 · Phase 1 · registry result, not featured evidence
13.8%Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
11.7%Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
3.3%Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
33.3%1000 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
50%1100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
50%900 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
33.3%600 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
0%400 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
100%200 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
66.7%100 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
66.7%50 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
33.3%25 mcg/day
NCT01286987 · Phase 1 · registry result, not featured evidence
16.7%Part 2: Talazoparib (Breast Cancer
NCT01286987 · Phase 1 · registry result, not featured evidence
33.3%Part 2: Talazoparib (Ewing Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
45.5%Part 2: Talazoparib (Ovarian/ Peri
NCT01286987 · Phase 1 · registry result, not featured evidence
60%Part 2: Talazoparib (Pancreatic Ca
NCT01286987 · Phase 1 · registry result, not featured evidence
0%Part 2: Talazoparib (Prostate Canc
NCT01286987 · Phase 1 · registry result, not featured evidence
34.8%Part 2: Talazoparib (SCLC Cancer)
NCT01286987 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
300 mg bdg
nausea 58%
anaemia 37.1%
vomiting 32.2%
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 6 more results
nausea 55.6%
anaemia 38.9%
asthenia 27.8%
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
constipation 100%
asthenia 66.7%
diarrhoea 66.7%
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
asthenia 100%
abdominal pain 0%
anaemia 0%
NCT04330040 · Phase 4 · registry result, not featured evidence
anaemia 36.8%
decreased appetite 13.2%
thrombocytopenia 13.2%
NCT04330040 · Phase 4 · registry result, not featured evidence
anaemia 50.9%
thrombocytopenia 21.7%
nausea 20.5%
NCT04330040 · Phase 4 · registry result, not featured evidence
asthenia 27.3%
abdominal pain upper 18.2%
headache 18.2%
NCT03205761 · Phase 2 · registry result, not featured evidence
h
anaemia 53.5%
fatigue 51.4%
nausea 49.7%
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
anemia 100%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT02401347 · Phase 2 · registry result, not featured evidence
fatigue 45%
nausea 45%
constipation 35%
NCT02401347 · Phase 2 · registry result, not featured evidence
anemia 75%
nausea 75%
fatigue 70%
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
anemia 69.2%
decreased white blood cells 61.5%
dizziness 61.5%
NCT02282345 · Phase 2 · registry result, not featured evidence
1.0 mg
anaemia 33.3%
platelet count decreased 33.3%
rash maculo-papular 33.3%
NCT03343054 · Phase 1 · registry result, not featured evidence
1.0 mg
anaemia 68.4%
neutrophil count decreased 63.2%
white blood cell count decreased 42.1%
NCT03343054 · Phase 1 · registry result, not featured evidence
0.75 mg
alanine aminotransferase increased 33.3%
arthralgia 33.3%
blood alkaline phosphatase increased 33.3%
NCT03343054 · Phase 1 · registry result, not featured evidence
anaemia 10.8%
nausea 10.8%
decreased appetite 7.7%
NCT04672460 · Phase 1 · registry result, not featured evidence
fatigue 18.3%
anaemia 13.3%
decreased appetite 8.3%
NCT04672460 · Phase 1 · registry result, not featured evidence
anaemia 16.7%
abdominal pain 6.7%
alopecia 6.7%
NCT04672460 · Phase 1 · registry result, not featured evidence
1000 mcg/day
fatigue 83.3%
alopecia 66.7%
anaemia 66.7%
NCT01286987 · Phase 1 · registry result, not featured evidence
1100 mcg/day
cough 50%
abdominal pain 33.3%
anaemia 33.3%
NCT01286987 · Phase 1 · registry result, not featured evidence
900 mcg/day
nausea 83.3%
alopecia 50%
constipation 50%
NCT01286987 · Phase 1 · registry result, not featured evidence
600 mcg/day
nausea 66.7%
wheezing 66.7%
cough 50%
NCT01286987 · Phase 1 · registry result, not featured evidence
400 mcg/day
fatigue 100%
constipation 66.7%
nausea 66.7%
NCT01286987 · Phase 1 · registry result, not featured evidence
200 mcg/day
nausea 100%
abdominal pain 66.7%
constipation 66.7%
NCT01286987 · Phase 1 · registry result, not featured evidence
100 mcg/day
fatigue 66.7%
abdominal distension 33.3%
abdominal pain 33.3%
NCT01286987 · Phase 1 · registry result, not featured evidence
50 mcg/day
flatulence 66.7%
abdominal pain 33.3%
anastomotic stenosis 33.3%
NCT01286987 · Phase 1 · registry result, not featured evidence
25 mcg/day
diarrhoea 66.7%
anxiety 33.3%
bundle branch block left 33.3%
NCT01286987 · Phase 1 · registry result, not featured evidence
fatigue 50%
alopecia 41.7%
anaemia 41.7%
NCT01286987 · Phase 1 · registry result, not featured evidence
anaemia 41.7%
arthralgia 33.3%
back pain 25%
NCT01286987 · Phase 1 · registry result, not featured evidence
nausea 90.9%
fatigue 81.8%
alopecia 54.5%
NCT01286987 · Phase 1 · registry result, not featured evidence
fatigue 40%
nausea 40%
abdominal pain 30%
NCT01286987 · Phase 1 · registry result, not featured evidence
constipation 66.7%
anaemia 33.3%
arthralgia 33.3%
NCT01286987 · Phase 1 · registry result, not featured evidence
fatigue 52.2%
nausea 39.1%
anaemia 34.8%
NCT01286987 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 1.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 2 versus Phase 1.
  7. gPopulation comparability has not been reviewed for 4 of these studies.
  8. hPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olaparib

ORR 59.9% (n=167) vs 28.8% (n=66) Chemotherapy300 mg bd
event count · % of participants
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to % from 100 Participants as posted
Overall Survival 24.94 months
time to event · months
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
8.9 months
NCT03205761 · Phase 2 · registry result, not featured evidence
ORR 49.6% (n=252)
responder rate · % of participants
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 36.4% (n=11) @ 8wk
event count · % of participants
No placebo or comparator arm
NCT03205761 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted

Talazoparib

ORR 62.6% (n=219) vs 27.2% (n=114) Physician's Choice Treatment
responder rate · % of participants
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 5.4 vs 3.1 Physician's Choice Treatment months
time to event · months
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Complete 0% (n=1) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Complete response (cR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 9 more results
0% (n=20) @ 24wk*
Complete response (cR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=1) @ 24wk*
Complete response (CR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=20) @ 24wk*
Complete response (CR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
5% (n=20)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 1 participants as posted
3.2% (n=31)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 1 participants as posted
0% (n=13)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=14)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=23)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=1)*
Complete Response (CR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
Partial 0% (n=1) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 9 more results
15% (n=20) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
0% (n=1) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
15% (n=20) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
35% (n=20)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 7 participants as posted
35.5% (n=31)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 11 participants as posted
15.4% (n=13)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=14)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
8.7% (n=23)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=1)*
Partial Response (PR)
NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted
ORR 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Overall response (CR+PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
15% (n=20) @ 24wk*
Overall response (CR+PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Stable Disease 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
35% (n=20) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=1) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
35% (n=20) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
Progressive Disease 100% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 3 more results
50% (n=20) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
100% (n=1) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
50% (n=20) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
Clinical Benefit 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Clinical benefit (CB)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
50% (n=20) @ 24wk*
Clinical benefit (CB)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
PFS-12 0% (n=1) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
5% (n=20) @ 52wk*
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
Pathological Complete 53.8% (n=13) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Residual Cancer Burden 0
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
show 1 more result
50% (n=20) @ 24wk*
Residual Cancer Burden 0
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted
Residual Cancer Burden III 0% (n=13) @ 24wk
event count · % of participants
No placebo or comparator arm
Residual Cancer Burden III
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
10% (n=20) @ 24wk*
Residual Cancer Burden III
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Tumor Size 88% (n=13) @ 8wk
percent change · % of baseline
No placebo or comparator arm
NCT02282345 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: PARP · full Breast Cancer pipeline

Olaparib

Marketed by AstraZeneca and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT02000622 · Phase 3 · completed

The trial randomly assigned 302 participants to olaparib or active chemotherapy, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, independently reviewed progression-free survival, was met: median PFS was 7.0 versus 4.2 months, with a hazard ratio of 0.58 (95% CI 0.43–0.80; p=0.0009).

Next expected readout: December 2026 · NCT03740893 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) (met)

Result source: NCT02000622

Talazoparib

Marketed by Pfizer and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT01945775 · Phase 3 · completed

Participants were randomized 2:1 to talazoparib or physician’s-choice chemotherapy, with 287 and 144 participants respectively, but treatment assignment was not blinded. The primary radiologic progression-free survival endpoint was met, with a statistically significant benefit for talazoparib; the open-label design and nonsignificant overall-survival result support a moderate evidence grade.

Next expected readout: January 2027 · NCT04039230 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) (met)

Result source: NCT01945775

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Olaparib: 6 of 6 rows · Talazoparib: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlaparibTalazoparib
Overall Survival
time to event · months
19.3 vs 19.6 Chemotherapy months300 mg bda,b,c
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more doses
19.3 vs 17.1 Chemotherapy months300 mg bd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
19.3 vs 17.1 Chemotherapy months300 mg bd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
19.3 vs 19.5 Physician's Choice Treatment monthsb,c
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS
time to event · months
7 vs 4.2 Chemotherapy months300 mg bda,b,c
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
7.4 vs 4.2 Chemotherapy months300 mg bd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
8.6 vs 5.6 Physician's Choice Treatment monthsb,c
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Dropout rate
82.4%300 mg bdd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
—Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
52.6%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
36.2%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT03205761 · Phase 2 · registry result, not featured evidence
50%
NCT03167619 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonee
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
0%Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
0%Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
5%Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
0%Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
—Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—300 mg bdd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
—Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
0%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
3.1%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
—
NCT03205761 · Phase 2 · registry result, not featured evidence
—
NCT03167619 · Phase 2 · registry result, not featured evidence · combination
—e
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
—Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
—Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
—Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
—Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
—Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
—Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
Serious AEs
18%300 mg bdd
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
12.7%Olaparib gBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
33.3%Olaparib sBRCAm Cohort
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
100%Both Ovarian Cancer and Breast Can
NCT04330040 · Phase 4 · registry result, not featured evidence
18.4%Breast Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
14.9%Ovarian Cancer
NCT04330040 · Phase 4 · registry result, not featured evidence
36.4%
NCT03205761 · Phase 2 · registry result, not featured evidence
13.6%
NCT03167619 · Phase 2 · registry result, not featured evidence · combination
36%e
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
0%Cohort A - Triple-negative Breast
NCT02401347 · Phase 2 · registry result, not featured evidence
15%Cohort B - HER2-negative Solid Tum
NCT02401347 · Phase 2 · registry result, not featured evidence
5%Expansion Arm Talazoparib (6 Month
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
0%Talazoparib (2 Months)
NCT02282345 · Phase 2 · registry result, not featured evidence
13.8%Treatment A: Commercial Capsule Fa
NCT04672460 · Phase 1 · registry result, not featured evidence
11.7%Treatment B: Soft Gel Capsule Fast
NCT04672460 · Phase 1 · registry result, not featured evidence
3.3%Treatment C: Soft Gel Capsule Fed
NCT04672460 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
300 mg bdd
nausea 58%
anaemia 37.1%
vomiting 32.2%
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
nausea 55.6%
anaemia 38.9%
asthenia 27.8%
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
constipation 100%
asthenia 66.7%
diarrhoea 66.7%
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
asthenia 100%
abdominal pain 0%
anaemia 0%
NCT04330040 · Phase 4 · registry result, not featured evidence
anaemia 36.8%
decreased appetite 13.2%
thrombocytopenia 13.2%
NCT04330040 · Phase 4 · registry result, not featured evidence
anaemia 50.9%
thrombocytopenia 21.7%
nausea 20.5%
NCT04330040 · Phase 4 · registry result, not featured evidence
asthenia 27.3%
abdominal pain upper 18.2%
headache 18.2%
NCT03205761 · Phase 2 · registry result, not featured evidence
decreased appetite 40.9%
nausea 40.9%
anaemia 31.8%
NCT03167619 · Phase 2 · registry result, not featured evidence · combination
e
anaemia 53.5%
fatigue 51.4%
nausea 49.7%
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
anemia 100%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT02401347 · Phase 2 · registry result, not featured evidence
fatigue 45%
nausea 45%
constipation 35%
NCT02401347 · Phase 2 · registry result, not featured evidence
anemia 75%
nausea 75%
fatigue 70%
NCT02282345 · Phase 2 · registry result, not featured evidence · combination
anemia 69.2%
decreased white blood cells 61.5%
dizziness 61.5%
NCT02282345 · Phase 2 · registry result, not featured evidence
anaemia 10.8%
nausea 10.8%
decreased appetite 7.7%
NCT04672460 · Phase 1 · registry result, not featured evidence
fatigue 18.3%
anaemia 13.3%
decreased appetite 8.3%
NCT04672460 · Phase 1 · registry result, not featured evidence
anaemia 16.7%
abdominal pain 6.7%
alopecia 6.7%
NCT04672460 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for 5 of these studies.
  5. ePopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olaparib

ORR 59.9% (n=167) vs 28.8% (n=66) Chemotherapy300 mg bd
event count · % of participants
NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to % from 100 Participants as posted
PFS 8.18 months
time to event · months
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
1.8 months @ 8wk
NCT03205761 · Phase 2 · registry result, not featured evidence
Overall Survival 24.94 months
time to event · months
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
8.9 months
NCT03205761 · Phase 2 · registry result, not featured evidence
18.27 months
NCT03167619 · Phase 2 · registry result, not featured evidence · combination
ORR 49.6% (n=252)
responder rate · % of participants
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 8 months
time to event · months
No placebo or comparator arm
NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
18.4 months
NCT03205761 · Phase 2 · registry result, not featured evidence
ORR 9.1% (n=11) @ 8wk
event count · % of participants
No placebo or comparator arm
NCT03205761 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 1 more result
13.6% (n=22)*
NCT03167619 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
Clinical Benefit 36.4% (n=11) @ 8wk
event count · % of participants
No placebo or comparator arm
NCT03205761 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
show 1 more result
36.4% (n=22)*
NCT03167619 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted

Talazoparib

ORR 62.6% (n=219) vs 27.2% (n=114) Physician's Choice Treatment
responder rate · % of participants
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 5.4 vs 3.1 Physician's Choice Treatment months
time to event · months
NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Complete 0% (n=1) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Complete response (cR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=20) @ 24wk*
Complete response (cR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=1) @ 24wk*
Complete response (CR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=20) @ 24wk*
Complete response (CR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Partial 0% (n=1) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
15% (n=20) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
0% (n=1) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
15% (n=20) @ 24wk*
Partial response (PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
ORR 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Overall response (CR+PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
15% (n=20) @ 24wk*
Overall response (CR+PR)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Stable Disease 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
35% (n=20) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=1) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
35% (n=20) @ 24wk*
Stable disease (SD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
Progressive Disease 100% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 3 more results
50% (n=20) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
100% (n=1) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
50% (n=20) @ 24wk*
Progressive disease (PD)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
Clinical Benefit 0% (n=1) @ 24wk
event count · % of participants
No placebo or comparator arm
Clinical benefit (CB)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
50% (n=20) @ 24wk*
Clinical benefit (CB)
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
PFS-12 0% (n=1) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 1 more result
5% (n=20) @ 52wk*
NCT02401347 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
Pathological Complete 53.8% (n=13) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Residual Cancer Burden 0
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
show 1 more result
50% (n=20) @ 24wk*
Residual Cancer Burden 0
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted
Residual Cancer Burden III 0% (n=13) @ 24wk
event count · % of participants
No placebo or comparator arm
Residual Cancer Burden III
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
10% (n=20) @ 24wk*
Residual Cancer Burden III
NCT02282345 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Tumor Size 88% (n=13) @ 8wk
percent change · % of baseline
No placebo or comparator arm
NCT02282345 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olaparib's landscape · Talazoparib's landscape